Seeking Alpha

AAIC 2012: Baxter's (BAX +1%) Gammagard immune system therapy for Alzheimer's disease performed...

AAIC 2012: Baxter's (BAX +1%) Gammagard immune system therapy for Alzheimer's disease performed well in Phase 2 trials, with 4 patients who received the most effective dose experiencing a stabilization over 3 years. It's all very small scale, and the proof will come early next year with the results of a larger Phase 3 study, but it's still really encouraging.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs